Abivax SA Sponsored ADR $ABVX Shares Bought by Saturn V Capital Management LP

Saturn V Capital Management LP lifted its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 12.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 622,479 shares of the company’s stock after buying an additional 69,553 shares during the quarter. Abivax makes up about 1.9% of Saturn V Capital Management LP’s investment portfolio, making the stock its 18th largest holding. Saturn V Capital Management LP owned approximately 0.82% of Abivax worth $4,762,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ABVX. Octagon Capital Advisors LP bought a new position in Abivax during the 1st quarter worth approximately $7,688,000. Affinity Asset Advisors LLC acquired a new position in Abivax in the first quarter worth $1,250,000. Allostery Investments LP increased its stake in Abivax by 86.0% during the first quarter. Allostery Investments LP now owns 1,099,654 shares of the company’s stock valued at $6,873,000 after purchasing an additional 508,401 shares during the last quarter. Aberdeen Group plc raised its holdings in shares of Abivax by 67.5% during the first quarter. Aberdeen Group plc now owns 710,516 shares of the company’s stock worth $4,441,000 after purchasing an additional 286,335 shares during the period. Finally, Paloma Partners Management Co bought a new position in shares of Abivax in the 1st quarter worth about $240,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Stock Performance

ABVX opened at $110.93 on Thursday. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $130.25. The stock’s fifty day moving average is $100.91 and its 200-day moving average is $62.46. The company has a market capitalization of $8.63 billion, a PE ratio of -64.12 and a beta of 0.48.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, September 8th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. On average, equities research analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ABVX. JMP Securities boosted their price objective on shares of Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a research report on Thursday, September 25th. BTIG Research lifted their target price on Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research report on Tuesday, November 4th. Truist Financial set a $140.00 price target on Abivax in a report on Monday, November 24th. Finally, Wolfe Research upgraded Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

Abivax Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.